5 citations
,
February 2024 in “Clinical Pharmacokinetics” This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.
17 citations
,
July 2024 in “Frontiers in Oncology” This review discusses recent advances in understanding Merkel cell carcinoma biology, including the development of genetically-engineered mouse models and potential therapeutic targets, but reports no new clinical results.
In this study, a Monte Carlo-generated synthetic cohort analysis found that higher simulated cannabis exposure was linked to increased self-assessed hair loss severity and reduced follicular density, suggesting potential connections worth exploring in further clinical research.
In this simulation study, higher cannabis exposure was associated with increased hair shedding severity and reduced follicular density, with greater effects observed in female-assigned profiles, but these associations are based on modeled data and not clinical observations.
